DGAP-Adhoc

Vita 34 AG decides on a capital increase of around 10%

DGAP-Ad-hoc: Vita 34 AG / Key word(s): Capital Increase Vita 34 AG decides on a capital increase of around 10% 13-Jun-2017 / 18:31 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. NOT FOR DISTRIBUTION, PUBLICATION OR DISCLOSURE IN OR WITHIN THE US, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION IS UNLAWFUL. PLEASE NOTE THE IMPORTANT NOTICES AT THE END OF THIS COMMUNICATION.

Vita 34 AG decides on a capital increase of around 10%

- Strategic investor MK Beleggingsmaatschappij Venlo B.V. (Netherlands) to acquire a stake in Vita 34

- Issue Price of EUR 6.62

Leipzig, June 13, 2017 - The Management Board of Vita 34 AG in Leipzig (ISIN: DE000A0BL849, WKN: A0BL84) (the "Company"), with approval of the Supervisory Board, has decided to increase the Company's share capital by approximately 10 percent against cash contributions (the "Capital Increase"), partially using Authorized Capital 2014.

The statutory subscription right of current shareholders of Vita 34 AG has been excluded as subscription and acquisition are authorized only to MK Beleggingsmaatschappij Venlo B.V., Venlo (Netherlands) ("MKBV"). MKBV is a strategic investor focusing on the medical technology and pharmaceuticals industry.

The Company's share capital is to be increased by EUR 302,649.00 from its current level of EUR 3,026,500.00 to EUR 3,329,149.00 by issuing 302,649 new no-par value shares with each single share's nominal portion of the share capital of the Company at EUR 1.00 ("New Shares"). The New Shares are to be issued at a price of EUR 6.62 per New Share and are entitled to participate in profit from January 1, 2017.

The New Shares are to be admitted to trading without a prospectus on the Regulated Market of the Frankfurt Stock Exchange with further admission requirements (Prime Standard).

The gross proceeds of approximately EUR 2 million from this private placement will be used to finance parts of the acquisition of the Seracell AG, Berlin.